DEFA14A: Monogram Tech Updates Shareholders on Zimmer Biomet Deal

Monogram Technologies Inc. informed shareholders about a new FAQ section on its Investor Relations page providing details on the proposed acquisition by Zimmer Biomet Holdings, Inc.

Summary

• Monogram Technologies Inc. sent an email to its stockholders on July 30, 2025.
• The email directs stockholders to the Frequently Asked Questions (FAQs) section on the company's Investor Relations page.
• The FAQs provide information regarding the previously announced proposed acquisition by Zimmer Biomet Holdings, Inc.
• The acquisition was initially announced on July 14, 2025.
• The FAQs specifically address the structure of the Contingent Value Right (CVR) and the total potential consideration related to the transaction.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive, as it indicates proactive communication and transparency with shareholders regarding a significant corporate transaction, which is generally viewed favorably.

Positives

• The company is providing increased clarity to shareholders regarding the proposed acquisition terms and timing through a dedicated FAQ section.
• The communication addresses key shareholder questions, including the CVR structure and total potential consideration.

Future Outlook

The company is progressing with the proposed acquisition by Zimmer Biomet Holdings, Inc., and is providing ongoing clarity to shareholders regarding the transaction's structure, including the CVR and total potential consideration.

Management Comments

• "We've added a Frequently Asked Questions (FAQ) section to our Investor Relations page to address many of the questions we've been receiving about the transaction, including the structure of the CVR and the total potential consideration."
• "We encourage all shareholders to review this information for clarity on the transaction terms and timing."
• "Thank you for your continued support."

Industry Context

This announcement is a procedural update within the medical technology and orthopedic industry, signaling progress on a significant merger and acquisition (M&A) event. The acquisition of Monogram Technologies by Zimmer Biomet, a major player in the musculoskeletal healthcare market, reflects ongoing consolidation and strategic realignments within the sector, often driven by innovation in areas like personalized medicine and robotics.

Stakeholder Impact

• Shareholders: Provided with clearer information regarding the terms and timing of the proposed acquisition, including details on the CVR and potential consideration.

Next Steps

• Shareholders are encouraged to review the FAQ section on the company's Investor Relations page for clarity on transaction terms and timing.

Key Dates

Recommendation

This filing is a procedural update providing clarity on an ongoing acquisition rather than new financial performance data. While the acquisition itself is price-sensitive, this specific communication does not introduce new information that would fundamentally alter an investment thesis beyond the initial acquisition announcement. Investors would likely hold their position while awaiting further developments or the closing of the transaction.

Keywords

Monogram Technologies, Zimmer Biomet, Acquisition, Merger, MGRM, Medical Technology, Orthopedics, SEC Filing, Shareholder Communication, CVR